Polaryx Therapeutics Welcomes New Members of the Board of Directors

PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announces the appointments of Mitchel Berger, M.D., Francis A. Braun III, CPA, and Charles Ryan, J.D., Ph.D. to Polaryx’s Board of Directors, effective January 29, 2026. In addition, Andrew O ceased serving as a member ...